Skip to main content
. 2013 Feb 4;3:9. doi: 10.3389/fonc.2013.00009

Table 1.

IGF-1R inhibitors in Ewing sarcoma (adapted from Maki, 2012).

Reference Drug Phase Response (%)
Pappo etal. (2011) R1507 II 11/115 (9.6)
Juergens etal. (2011) Figitumumab I–II 15/106 (14)
Malempati etal. (2012) Cixutumumab I–II 1/35 (2.9)
Tap etal. (2012) Ganitumab II 1/18 (5.6)
Tolcher etal. (2009) Ganitumab I+tail 2/12 (16)
Olmos etal. (2010) Figitumumab I-II 2/16 (12)
TOTAL 41/312 (13)